Safety and Pharmacokinetics of TT30 in Subjects With Paroxysmal Nocturnal Hemoglobinuria (PNH)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01335165|
Recruitment Status : Terminated (Inability to reach enrollment as planned)
First Posted : April 14, 2011
Last Update Posted : May 22, 2014
|Condition or disease||Intervention/treatment||Phase|
|Paroxysmal Nocturnal Hemoglobinuria (PNH)||Drug: ALXN1102 Drug: ALXN1103||Phase 1|
This is an open-label, single-dose, dose-escalation study to assess the safety, tolerability, PK, PD, and immunogenicity of TT30 given as an IV infusion and as a SC injection in subjects with PNH or evidence of circulating PNH cells.
Eligible subjects with PNH will be vaccinated with meningococcal vaccine at least two weeks prior to dosing (if not previously vaccinated or if revaccination is required).
On study day 1, the subject will receive the single dose of TT30 as an IV infusion over 60 minutes or as a SC injection, and be followed with additional study evaluations over the next 59 days.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||10 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Phase 1, Single Ascending Dose Study of the Safety and Pharmacokinetics of TT30 in Subjects With Paroxysmal Nocturnal Hemoglobinuria (PNH)|
|Study Start Date :||April 2011|
|Primary Completion Date :||March 2014|
|Study Completion Date :||March 2014|
Experimental: TT30 (ALXN1102 Formulation)
IV: 0.1, 0.3, and 1.0 mg/kg
Single Ascending Dose IV
Experimental: TT30 (ALXN1103 Formulation)
IV: 3.0, 6.0, and 10.0 mg/kg
SC: 1.0 and 3.0 mg/kg
Single Ascending Dose IV or SC
- Assess the safety and tolerability of a single dose of TT30. [ Time Frame: 60 days ]Safety and tolerability will be evaluated in all subjects by physical exam, vital signs, ECGs, laboratory changes over time, adverse events, and antibody development.
- Characterize PK, PD and immunogenicity of a single dose of TT30. [ Time Frame: 60 days ]Immunogenicity will be will be assessed using standard measures for these parameters. PK and PD will be assessed by using standard measures, including reticulocyte count and lactate dehydrogenase (LDH) levels.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01335165
|United States, California|
|USC/Norris Comprehensive Cancer Center|
|Los Angeles, California, United States, 90033|
|Institute of Hematology and Blood Transfusion / Institut Hematologie a krevní transfuze|
|U nemocnice 1, Prague 2, Czech Republic, 128 08|
|Federico II University of Naples|
|Via Pansini 5, Naples, Italy, 80131|
|University Clinical Centre|
|Dębinki 7, Gdańsk, Poland, 80-952|
|King's College Hospital NHS Foundation Trust|
|Denmark Hill, London, United Kingdom, SE5 9RS UK|
|Study Director:||Bill Lundberg, MD||Alexion Pharmaceuticals|